Barclays Starts Alnylam Pharmaceuticals (ALNY) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $158.00 -4.24%
Rating Summary:
26 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
26 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Barclays analyst Eliana Merle initiates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Overweight rating and a price target of $527.00.
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $361.35 yesterday.
You May Also Be Interested In
- Truist Securities Downgrades Alnylam Pharmaceuticals (ALNY) to Hold
- Wedbush Starts Terrestrial Energy Inc. (IMSR) at Neutral
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Freedom Broker
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
